SPX:SPREADEXSPX 500, Daily Analysis
Data as of 2026-06-14 - not real-time
$230.05
Latest Price
8/10Risk
Risk Level: High
Executive Summary
SPX Technologies is trading at $230.05, comfortably above its 20‑day SMA of $218.75 and 50‑day SMA of $214.63, with a bullish MACD histogram (+$1.03) and rising volume, indicating short‑term momentum strength. RSI sits at 58.5, suggesting room for upside without immediate overbought pressure, while the price remains well within the technical range bounded by a support of $191.24 and resistance near $244.64.
Fundamentally, the company posted a 17.4% YoY revenue growth and maintains healthy operating (16.6%) and profit margins (10.8%). Forward earnings are projected at $9.06, cutting the forward P/E to 25.4 versus a trailing P/E of 44.1, and analysts (12) rate it a strong buy with a median target of $267.5, implying about a 15% upside. However, the current valuation appears stretched relative to peers (industry PE ~30.6) and a DCF fair value of $86.79, highlighting potential overvaluation.
Risk factors include elevated 30‑day volatility (42%) and a beta above 1.3, reflecting sensitivity to market swings, combined with a high debt‑to‑equity ratio (~29.5) and no dividend payout. The industrial building‑products sector adds cyclical exposure, while geographic diversification across North America, Europe, and China introduces moderate regulatory and currency considerations.
Fundamentally, the company posted a 17.4% YoY revenue growth and maintains healthy operating (16.6%) and profit margins (10.8%). Forward earnings are projected at $9.06, cutting the forward P/E to 25.4 versus a trailing P/E of 44.1, and analysts (12) rate it a strong buy with a median target of $267.5, implying about a 15% upside. However, the current valuation appears stretched relative to peers (industry PE ~30.6) and a DCF fair value of $86.79, highlighting potential overvaluation.
Risk factors include elevated 30‑day volatility (42%) and a beta above 1.3, reflecting sensitivity to market swings, combined with a high debt‑to‑equity ratio (~29.5) and no dividend payout. The industrial building‑products sector adds cyclical exposure, while geographic diversification across North America, Europe, and China introduces moderate regulatory and currency considerations.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above 20‑day and 50‑day SMAs
- Bullish MACD and increasing volume
- High current P/E relative to industry
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 17% revenue growth and expanding margins
- Forward P/E of 25 indicating earnings acceleration
- Analyst consensus strong‑buy with ~15% target upside
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Robust cash flow generation versus elevated debt levels
- Cyclical exposure in industrial sector
- Absence of dividend and high valuation metrics
Key Metrics & Analysis
Financial Health
Revenue Growth17.40%
Profit Margin10.76%
P/E Ratio44.1
ROE13.85%
ROA6.53%
Debt/Equity29.49
P/B Ratio5.0
Op. Cash Flow$374.8M
Free Cash Flow$179.2M
Industry P/E30.6
Technical Analysis
TrendBullish
RSI58.5
Support$191.24
Resistance$244.64
MA 20$218.75
MA 50$214.63
MA 200$207.92
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value$86.79
Target Price$266.25
Upside/Downside15.74%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.36
Volatility42.26%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.